Application
Western blot analysis of anti-PLAU Antibody in mouse brain tissue lysates (35ug/lane)Application
Western blot analysis of anti-PLAU Antibody in A2058 cell line lysates (35ug/lane)Application
Formalin-fixed and paraffin-embedded human prostata carcinoma tissue reacted with PLAU antibody (N-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining.Application
Flow cytometric analysis of A2058 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.| Product Name | Urokinase Antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | Urokinase-type plasminogen activator, U-plasminogen activator, uPA, Urokinase-type plasminogen activator long chain A, Urokinase-type plasminogen activator short chain A, Urokinase-type plasminogen activator chain B, PLAU |
| Product description | PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.1) Strausberg, R.L., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16899-16903 (2002). Sperl, S., et al., Proc. Natl. Acad. Sci. U.S.A. 97(10):5113-5118 (2000). Turkmen, B., et al., Electrophoresis 18(5):686-689 (1997). Conne, B., et al., Thromb. Haemost. 77(3):434-435 (1997). Yoshimoto, M., et al., Biochim. Biophys. Acta 1293(1):83-89 (1996). |
| Immunogen | This Urokinase (PLAU) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 60-90 amino acids from the N-terminal region of human Urokinase (PLAU). |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | FACSIHC-PWB |
| For WB starting dilution is: 1:1000 For IHC-P starting dilution is: 1:10~50 For FACS starting dilution is: 1:10~50: |
|
| Species Reactivity | HumanMouse |
| Concentration | 1mg/ml |
| Gene Symbol | PLAU |
|---|---|
| Alternative Names | Urokinase-type plasminogen activator U-plasminogen activator uPA Urokinase-type plasminogen activator long chain A Urokinase-type plasminogen activator short chain A Urokinase-type plasminogen activator chain B PLAU |
| Molecular Weight(MW) | 49 kDa |
Application
Western blot analysis of anti-PLAU Antibody in mouse brain tissue lysates (35ug/lane)
Application
Western blot analysis of anti-PLAU Antibody in A2058 cell line lysates (35ug/lane)
Application
Formalin-fixed and paraffin-embedded human prostata carcinoma tissue reacted with PLAU antibody (N-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining.
Application
Flow cytometric analysis of A2058 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.| Application Notes | For WB starting dilution is: 1:1000 For IHC-P starting dilution is: 1:10~50 For FACS starting dilution is: 1:10~50: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| Storage Buffer | Supplied in PBS with 0.09% (W/V) sodium azide. |
